Source: ALL

Variant Gene Disease Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs1418810723
rs1418810723
FN1
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.030 GeneticVariation BEFREE In particular, FN1 mRNA levels were higher in tumor vs non-tumor tissue (117.3, p < 0.001) and also in aggressive and BRAF(V600E) samples. 27173027

2016
dbSNP: rs1418810723
rs1418810723
FN1
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.030 GeneticVariation BEFREE Patients with PTC harboring the BRAF(V600E) mutation seem to display a more aggressive clinical behavior, but little is known about the role of this mutation in crucial processes in the tumor microenvironment, such as tumor adhesion, migration, invasion, and metastasis. 21447745

2011
dbSNP: rs1418810723
rs1418810723
FN1
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.030 GeneticVariation BEFREE Tumor-derived fibronectin is involved in melanoma cell invasion and regulated by V600E B-Raf signaling pathway. 16960555

2007
dbSNP: rs1418810723
rs1418810723
FN1
CUI: C0238463
Disease: Papillary thyroid carcinoma
Papillary thyroid carcinoma 		0.020 GeneticVariation BEFREE This review focuses on the recent progress in understanding the role of BRAF(V600E) in the regulation of some ECM noncellular components and trans-membrane receptors of the microenvironment in PTC in order to design novel targeted therapies directed at the BRAF(V600E) multifaceted signaling cascades. 21447745

2011
dbSNP: rs1418810723
rs1418810723
FN1
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.020 GeneticVariation BEFREE Patients with PTC harboring the BRAF(V600E) mutation seem to display a more aggressive clinical behavior, but little is known about the role of this mutation in crucial processes in the tumor microenvironment, such as tumor adhesion, migration, invasion, and metastasis. 21447745

2011
dbSNP: rs1418810723
rs1418810723
FN1
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.020 GeneticVariation BEFREE Tumor-derived fibronectin is involved in melanoma cell invasion and regulated by V600E B-Raf signaling pathway. 16960555

2007
dbSNP: rs1418810723
rs1418810723
FN1
CUI: C0238463
Disease: Papillary thyroid carcinoma
Papillary thyroid carcinoma 		0.020 GeneticVariation BEFREE The B-Raf gene was mutated with a T-->A transversion at nucleotide 1799 (V600E) in 8 of 10 differentiated PTC, and in 4 of 7 aggressive carcinomas. 16676402

2006
dbSNP: rs1418810723
rs1418810723
FN1
CUI: C0040136
Disease: Thyroid Neoplasm
Thyroid Neoplasm 		0.010 GeneticVariation BEFREE BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression. 21447745

2011
dbSNP: rs1418810723
rs1418810723
FN1
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma 		0.010 GeneticVariation BEFREE BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression. 21447745

2011
dbSNP: rs1418810723
rs1418810723
FN1
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.010 GeneticVariation BEFREE BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression. 21447745

2011
dbSNP: rs1418810723
rs1418810723
FN1
CUI: C0007115
Disease: Malignant neoplasm of thyroid
Malignant neoplasm of thyroid 		0.010 GeneticVariation BEFREE BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression. 21447745

2011
dbSNP: rs1418810723
rs1418810723
FN1
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis 		0.010 GeneticVariation BEFREE Patients with PTC harboring the BRAF(V600E) mutation seem to display a more aggressive clinical behavior, but little is known about the role of this mutation in crucial processes in the tumor microenvironment, such as tumor adhesion, migration, invasion, and metastasis. 21447745

2011
dbSNP: rs1418810723
rs1418810723
FN1
CUI: C0007097
Disease: Carcinoma
Carcinoma 		0.010 GeneticVariation BEFREE The B-Raf gene was mutated with a T-->A transversion at nucleotide 1799 (V600E) in 8 of 10 differentiated PTC, and in 4 of 7 aggressive carcinomas. 16676402

2006